Pulmonary Arterial Hypertension
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.
Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.
A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.
Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.
Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.
Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.
A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.
The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.
The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.
Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.
There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.
Researchers raise issues regarding interpretation of clinical trial results in the field of pulmonary arterial hypertension.
Researchers modified the inhalation technique of iloprost in a patient with pulmonary arterial hypertension by attaching a nasal cannula to the inhalator's inlet port, shortening the administration duration.
The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.
Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.
Clinical worsening in pediatric pulmonary arterial hypertension may be predicted using right ventricular stroke work indexed by ejection fraction.
The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.
There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.
Poor subpleural perfusion in patients with nonoperable chronic thromboembolic pulmonary hypertension may predict balloon pulmonary angioplasty failure.
Although metformin prevented the development of PAH in hypoxia and monocrotalinerat models and reversed PAH in SU5416/hypoxia rats, it failed to reverse pulmonary pressures and vascular remodeling in mice with SU5416/hypoxia-induced PAH.
Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus in pulmonary arterial hypertension should be considered separate diseases.
The Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire has good psychometric properties and can be administered in clinical practice.
Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.
In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.
Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.
Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.